Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Breast Cancer
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1413674
This article is part of the Research Topic The Exciting Opportunities and Challenges for Targeting “HER2 low” Breast Cancers and Beyond View all articles

Prognosis in HR-positive metastatic breast cancer with HER2-low versus HER2-zero treated with CDK4/6 inhibitor and endocrine therapy: a meta-analysis

Provisionally accepted
Lin-Yu Xia Lin-Yu Xia 1*Xu-Chen Cao Xu-Chen Cao 2Qing-Lin Hu Qing-Lin Hu 1Wei-Yun Xu Wei-Yun Xu 3
  • 1 First Affiliated Hospital of Chengdu Medical College, Chengdu, China
  • 2 Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
  • 3 Mianyang Central Hospital, Mianyang, Sichuan Province, China

The final, formatted version of the article will be published soon.

    The combination of CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) is currently the standard first-line treatment for patients with metastatic hormone receptor positive (HR+), and HER2-negative (HER2-) breast cancer. However, the impact of HER2 status on the prognosis of patients receiving CDK4/6i and ET remains unclear. The meta-analysis was conducted to evaluate different outcomes between HER2-low and HER2-zero patients in advanced HR+ breast cancer receiving CDK4/6i and ET. Methods: A systematic search was performed in PubMed and EMBASE databases for relevant published literature. Objective response rate (ORR), overall survival (OS), and progression-free survival (PFS) were pooled by fixed or random effects models. Results: Overall, 12 studies with 3567 patients were eligible for analysis. The pooled analysis suggested that no significant differences were observed in terms of ORR and OS between HER2-low and HER2-zero patients who underwent CDK4/6i and ET. Similarly, no significant difference in PFS was found between HER2-low and HER2-zero patients who underwent post-line CDK4/6i and ET or first-line Palbociclib and ET.However, in patients who received mixed-line ( not a single treatment line) or first-line CDK4/6i and ET, the PFS was significantly shorter in the HER2-low subgroup than in the HER2-zero subgroup

    Keywords: breast cancer, HER2-low, CDK4/6 inhibitor, Endocrine therapy, Prog nosis

    Received: 07 Apr 2024; Accepted: 31 Jul 2024.

    Copyright: © 2024 Xia, Cao, Hu and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Lin-Yu Xia, First Affiliated Hospital of Chengdu Medical College, Chengdu, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.